T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: A case report

Cases Journal

Volumn 3, Issue 1, 2010, Pages

  Singhal, Manish ^a   Raina, Vinod ^a   Gupta, Ritu ^a   Das, Prasenjit ^b  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; TAMOXIFEN;

ADULT; ARTICLE; ASPIRATION BIOPSY; BREAST CARCINOMA; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; FEMALE; HEPATOMEGALY; HUMAN; IMMUNOPHENOTYPING; LUNG METASTASIS; LYMPH NODE METASTASIS; MASTECTOMY; MICROPHOTOGRAPHY; MULTIPLE CYCLE TREATMENT; PROLYMPHOCYTIC LEUKEMIA;

EID: 77953443054     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.1186/1757-1626-3-4     Document Type: Article

References (11)

1. Fisher B, Rockette H, Fisher ER, Wickerham DL, Redmond C, Brown A: Leukemia in Breast Cancer Patients Following Adjuvant Chemotherapy or Postoperative Radiation: The NSABP Experience. J Clin Oncol 1985, 3:1640-1658.
2. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN: Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992, 326:1745-1751.
3. Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M, Hortobagyi GN: Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 1996, 14:2722-2730.
4. Smith RE: Risk for the development of treatment-related acute myelocytic leukemia andmyelodysplastic syndrome among patients withbreast cancer: Review of the literature and theNational Surgical Adjuvant Breast and Bowel Projectexperience. Clin Breast Cancer 2003, 4:273-279.
5. Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D: Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005, 23:4179-4191.
6. Le Deley MC, Suzan F, Cutuli B, Delaloge S, Shamsaldin A, Linassier C, Clisant S, de Vathaire F, Fenaux P, Hill C: Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: Risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 2007, 25:292-300.
7. Chakraborty S, Sun CL, Francisco L, Sabado M, Li L, Chang KL, Forman S, Bhatia S, Bhatia R: Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 2009, 27:791-798.
8. Tadeusz R, Pawe? R: Current treatment options in prolymphocytic leukemia. Med Sci Monit 2009, 13:RA69-80.
9. Friedenson B: The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BioMed Central Cancer 2007, 7:152-163.
10. Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D: High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001, 98:1721-1726.
11. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D: The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994, 12:2588-2593.